Report Detail

Request for Sample of this report

Other Global Isocitrate Dehydrogenase Inhibitors Market 2024 by Company, Regions, Type and Application, Forecast to 2030

  • RnM3609556
    • |
  • 13 August, 2024
    • |
  • Global
    • |
  • 114 Pages
    • |
  • GIR (Global Info Research)
    • |
  • Other

According to our (Global Info Research) latest study, the global Isocitrate Dehydrogenase Inhibitors market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
Isocitrate dehydrogenase (IDH) (EC 1.1.1.42) and (EC 1.1.1.41) is an enzyme that catalyzes the oxidative decarboxylation of isocitrate, producing alpha-ketoglutarate (α-ketoglutarate) and CO2.
Specific mutations in the isocitrate dehydrogenase gene IDH1 have been found in several brain tumors including astrocytoma, oligodendroglioma and glioblastoma multiforme, with mutations found in nearly all cases of secondary glioblastomas, which develop from lower-grade gliomas, but rarely in primary high-grade glioblastoma multiforme.Patients whose tumor had an IDH1 mutation had longer survival. Furthermore, mutations of IDH2 and IDH1 were found in up to 20% of cytogenetically normal acute myeloid leukemia (AML).These mutations are known to produce (D)-2-hydroxyglutarate from alpha-ketoglutarate.(D)-2-hydroxyglutarate accumulates to very high concentrations which inhibits the function of enzymes that are dependent on alpha-ketoglutarate.This leads to a hypermethylated state of DNA and histones, which results in different gene expression that can activate oncogenes and inactivate tumor-suppressor genes. Ultimately, this may lead to the types of cancer described above.Isocitrate dehydrogenase inhibition technology can be effectively applied to the cancer market.
The Global Info Research report includes an overview of the development of the Isocitrate Dehydrogenase Inhibitors industry chain, the market status of DH Inhibitor (IDH1 Mutant Medullary Malignant Tumor, IDH2 Mutant Medullary Malignant Tumor), FLT3 Inhibitor (IDH1 Mutant Medullary Malignant Tumor, IDH2 Mutant Medullary Malignant Tumor), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Isocitrate Dehydrogenase Inhibitors.
Regionally, the report analyzes the Isocitrate Dehydrogenase Inhibitors markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Isocitrate Dehydrogenase Inhibitors market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Isocitrate Dehydrogenase Inhibitors market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Isocitrate Dehydrogenase Inhibitors industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., IDH1 Mutant Medullary Malignant Tumor, IDH2 Mutant Medullary Malignant Tumor).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Isocitrate Dehydrogenase Inhibitors market.
Regional Analysis: The report involves examining the Isocitrate Dehydrogenase Inhibitors market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Isocitrate Dehydrogenase Inhibitors market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Isocitrate Dehydrogenase Inhibitors:
Company Analysis: Report covers individual Isocitrate Dehydrogenase Inhibitors players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Isocitrate Dehydrogenase Inhibitors This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (DH Inhibitor, FLT3 Inhibitor).
Technology Analysis: Report covers specific technologies relevant to Isocitrate Dehydrogenase Inhibitors. It assesses the current state, advancements, and potential future developments in Isocitrate Dehydrogenase Inhibitors areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Isocitrate Dehydrogenase Inhibitors market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Isocitrate Dehydrogenase Inhibitors market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
IDH1 Mutant Medullary Malignant Tumor
IDH2 Mutant Medullary Malignant Tumor
Others
Market segment by Application
DH Inhibitor
FLT3 Inhibitor
Hedgehog Pathway Inhibitor
Others
Market segment by players, this report covers
AGIOS
Aslan Pharmaceuticals
Bayer
Beigene
Bristol-Myers Squibb
Celgene
Daiichi Sankyo
Philogen S.p.A.
Tesaro
Tragara/Adastra
Tocagen
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Isocitrate Dehydrogenase Inhibitors product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Isocitrate Dehydrogenase Inhibitors, with revenue, gross margin and global market share of Isocitrate Dehydrogenase Inhibitors from 2019 to 2024.
Chapter 3, the Isocitrate Dehydrogenase Inhibitors competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Isocitrate Dehydrogenase Inhibitors market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Isocitrate Dehydrogenase Inhibitors.
Chapter 13, to describe Isocitrate Dehydrogenase Inhibitors research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope of Isocitrate Dehydrogenase Inhibitors
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Isocitrate Dehydrogenase Inhibitors by Type
    • 1.3.1 Overview: Global Isocitrate Dehydrogenase Inhibitors Market Size by Type: 2019 Versus 2023 Versus 2030
    • 1.3.2 Global Isocitrate Dehydrogenase Inhibitors Consumption Value Market Share by Type in 2023
    • 1.3.3 IDH1 Mutant Medullary Malignant Tumor
    • 1.3.4 IDH2 Mutant Medullary Malignant Tumor
    • 1.3.5 Others
  • 1.4 Global Isocitrate Dehydrogenase Inhibitors Market by Application
    • 1.4.1 Overview: Global Isocitrate Dehydrogenase Inhibitors Market Size by Application: 2019 Versus 2023 Versus 2030
    • 1.4.2 DH Inhibitor
    • 1.4.3 FLT3 Inhibitor
    • 1.4.4 Hedgehog Pathway Inhibitor
    • 1.4.5 Others
  • 1.5 Global Isocitrate Dehydrogenase Inhibitors Market Size & Forecast
  • 1.6 Global Isocitrate Dehydrogenase Inhibitors Market Size and Forecast by Region
    • 1.6.1 Global Isocitrate Dehydrogenase Inhibitors Market Size by Region: 2019 VS 2023 VS 2030
    • 1.6.2 Global Isocitrate Dehydrogenase Inhibitors Market Size by Region, (2019-2030)
    • 1.6.3 North America Isocitrate Dehydrogenase Inhibitors Market Size and Prospect (2019-2030)
    • 1.6.4 Europe Isocitrate Dehydrogenase Inhibitors Market Size and Prospect (2019-2030)
    • 1.6.5 Asia-Pacific Isocitrate Dehydrogenase Inhibitors Market Size and Prospect (2019-2030)
    • 1.6.6 South America Isocitrate Dehydrogenase Inhibitors Market Size and Prospect (2019-2030)
    • 1.6.7 Middle East and Africa Isocitrate Dehydrogenase Inhibitors Market Size and Prospect (2019-2030)

2 Company Profiles

  • 2.1 AGIOS
    • 2.1.1 AGIOS Details
    • 2.1.2 AGIOS Major Business
    • 2.1.3 AGIOS Isocitrate Dehydrogenase Inhibitors Product and Solutions
    • 2.1.4 AGIOS Isocitrate Dehydrogenase Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
    • 2.1.5 AGIOS Recent Developments and Future Plans
  • 2.2 Aslan Pharmaceuticals
    • 2.2.1 Aslan Pharmaceuticals Details
    • 2.2.2 Aslan Pharmaceuticals Major Business
    • 2.2.3 Aslan Pharmaceuticals Isocitrate Dehydrogenase Inhibitors Product and Solutions
    • 2.2.4 Aslan Pharmaceuticals Isocitrate Dehydrogenase Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
    • 2.2.5 Aslan Pharmaceuticals Recent Developments and Future Plans
  • 2.3 Bayer
    • 2.3.1 Bayer Details
    • 2.3.2 Bayer Major Business
    • 2.3.3 Bayer Isocitrate Dehydrogenase Inhibitors Product and Solutions
    • 2.3.4 Bayer Isocitrate Dehydrogenase Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
    • 2.3.5 Bayer Recent Developments and Future Plans
  • 2.4 Beigene
    • 2.4.1 Beigene Details
    • 2.4.2 Beigene Major Business
    • 2.4.3 Beigene Isocitrate Dehydrogenase Inhibitors Product and Solutions
    • 2.4.4 Beigene Isocitrate Dehydrogenase Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
    • 2.4.5 Beigene Recent Developments and Future Plans
  • 2.5 Bristol-Myers Squibb
    • 2.5.1 Bristol-Myers Squibb Details
    • 2.5.2 Bristol-Myers Squibb Major Business
    • 2.5.3 Bristol-Myers Squibb Isocitrate Dehydrogenase Inhibitors Product and Solutions
    • 2.5.4 Bristol-Myers Squibb Isocitrate Dehydrogenase Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
    • 2.5.5 Bristol-Myers Squibb Recent Developments and Future Plans
  • 2.6 Celgene
    • 2.6.1 Celgene Details
    • 2.6.2 Celgene Major Business
    • 2.6.3 Celgene Isocitrate Dehydrogenase Inhibitors Product and Solutions
    • 2.6.4 Celgene Isocitrate Dehydrogenase Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
    • 2.6.5 Celgene Recent Developments and Future Plans
  • 2.7 Daiichi Sankyo
    • 2.7.1 Daiichi Sankyo Details
    • 2.7.2 Daiichi Sankyo Major Business
    • 2.7.3 Daiichi Sankyo Isocitrate Dehydrogenase Inhibitors Product and Solutions
    • 2.7.4 Daiichi Sankyo Isocitrate Dehydrogenase Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
    • 2.7.5 Daiichi Sankyo Recent Developments and Future Plans
  • 2.8 Philogen S.p.A.
    • 2.8.1 Philogen S.p.A. Details
    • 2.8.2 Philogen S.p.A. Major Business
    • 2.8.3 Philogen S.p.A. Isocitrate Dehydrogenase Inhibitors Product and Solutions
    • 2.8.4 Philogen S.p.A. Isocitrate Dehydrogenase Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
    • 2.8.5 Philogen S.p.A. Recent Developments and Future Plans
  • 2.9 Tesaro
    • 2.9.1 Tesaro Details
    • 2.9.2 Tesaro Major Business
    • 2.9.3 Tesaro Isocitrate Dehydrogenase Inhibitors Product and Solutions
    • 2.9.4 Tesaro Isocitrate Dehydrogenase Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
    • 2.9.5 Tesaro Recent Developments and Future Plans
  • 2.10 Tragara/Adastra
    • 2.10.1 Tragara/Adastra Details
    • 2.10.2 Tragara/Adastra Major Business
    • 2.10.3 Tragara/Adastra Isocitrate Dehydrogenase Inhibitors Product and Solutions
    • 2.10.4 Tragara/Adastra Isocitrate Dehydrogenase Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
    • 2.10.5 Tragara/Adastra Recent Developments and Future Plans
  • 2.11 Tocagen
    • 2.11.1 Tocagen Details
    • 2.11.2 Tocagen Major Business
    • 2.11.3 Tocagen Isocitrate Dehydrogenase Inhibitors Product and Solutions
    • 2.11.4 Tocagen Isocitrate Dehydrogenase Inhibitors Revenue, Gross Margin and Market Share (2019-2024)
    • 2.11.5 Tocagen Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Isocitrate Dehydrogenase Inhibitors Revenue and Share by Players (2019-2024)
  • 3.2 Market Share Analysis (2023)
    • 3.2.1 Market Share of Isocitrate Dehydrogenase Inhibitors by Company Revenue
    • 3.2.2 Top 3 Isocitrate Dehydrogenase Inhibitors Players Market Share in 2023
    • 3.2.3 Top 6 Isocitrate Dehydrogenase Inhibitors Players Market Share in 2023
  • 3.3 Isocitrate Dehydrogenase Inhibitors Market: Overall Company Footprint Analysis
    • 3.3.1 Isocitrate Dehydrogenase Inhibitors Market: Region Footprint
    • 3.3.2 Isocitrate Dehydrogenase Inhibitors Market: Company Product Type Footprint
    • 3.3.3 Isocitrate Dehydrogenase Inhibitors Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Isocitrate Dehydrogenase Inhibitors Consumption Value and Market Share by Type (2019-2024)
  • 4.2 Global Isocitrate Dehydrogenase Inhibitors Market Forecast by Type (2025-2030)

5 Market Size Segment by Application

  • 5.1 Global Isocitrate Dehydrogenase Inhibitors Consumption Value Market Share by Application (2019-2024)
  • 5.2 Global Isocitrate Dehydrogenase Inhibitors Market Forecast by Application (2025-2030)

6 North America

  • 6.1 North America Isocitrate Dehydrogenase Inhibitors Consumption Value by Type (2019-2030)
  • 6.2 North America Isocitrate Dehydrogenase Inhibitors Consumption Value by Application (2019-2030)
  • 6.3 North America Isocitrate Dehydrogenase Inhibitors Market Size by Country
    • 6.3.1 North America Isocitrate Dehydrogenase Inhibitors Consumption Value by Country (2019-2030)
    • 6.3.2 United States Isocitrate Dehydrogenase Inhibitors Market Size and Forecast (2019-2030)
    • 6.3.3 Canada Isocitrate Dehydrogenase Inhibitors Market Size and Forecast (2019-2030)
    • 6.3.4 Mexico Isocitrate Dehydrogenase Inhibitors Market Size and Forecast (2019-2030)

7 Europe

  • 7.1 Europe Isocitrate Dehydrogenase Inhibitors Consumption Value by Type (2019-2030)
  • 7.2 Europe Isocitrate Dehydrogenase Inhibitors Consumption Value by Application (2019-2030)
  • 7.3 Europe Isocitrate Dehydrogenase Inhibitors Market Size by Country
    • 7.3.1 Europe Isocitrate Dehydrogenase Inhibitors Consumption Value by Country (2019-2030)
    • 7.3.2 Germany Isocitrate Dehydrogenase Inhibitors Market Size and Forecast (2019-2030)
    • 7.3.3 France Isocitrate Dehydrogenase Inhibitors Market Size and Forecast (2019-2030)
    • 7.3.4 United Kingdom Isocitrate Dehydrogenase Inhibitors Market Size and Forecast (2019-2030)
    • 7.3.5 Russia Isocitrate Dehydrogenase Inhibitors Market Size and Forecast (2019-2030)
    • 7.3.6 Italy Isocitrate Dehydrogenase Inhibitors Market Size and Forecast (2019-2030)

8 Asia-Pacific

  • 8.1 Asia-Pacific Isocitrate Dehydrogenase Inhibitors Consumption Value by Type (2019-2030)
  • 8.2 Asia-Pacific Isocitrate Dehydrogenase Inhibitors Consumption Value by Application (2019-2030)
  • 8.3 Asia-Pacific Isocitrate Dehydrogenase Inhibitors Market Size by Region
    • 8.3.1 Asia-Pacific Isocitrate Dehydrogenase Inhibitors Consumption Value by Region (2019-2030)
    • 8.3.2 China Isocitrate Dehydrogenase Inhibitors Market Size and Forecast (2019-2030)
    • 8.3.3 Japan Isocitrate Dehydrogenase Inhibitors Market Size and Forecast (2019-2030)
    • 8.3.4 South Korea Isocitrate Dehydrogenase Inhibitors Market Size and Forecast (2019-2030)
    • 8.3.5 India Isocitrate Dehydrogenase Inhibitors Market Size and Forecast (2019-2030)
    • 8.3.6 Southeast Asia Isocitrate Dehydrogenase Inhibitors Market Size and Forecast (2019-2030)
    • 8.3.7 Australia Isocitrate Dehydrogenase Inhibitors Market Size and Forecast (2019-2030)

9 South America

  • 9.1 South America Isocitrate Dehydrogenase Inhibitors Consumption Value by Type (2019-2030)
  • 9.2 South America Isocitrate Dehydrogenase Inhibitors Consumption Value by Application (2019-2030)
  • 9.3 South America Isocitrate Dehydrogenase Inhibitors Market Size by Country
    • 9.3.1 South America Isocitrate Dehydrogenase Inhibitors Consumption Value by Country (2019-2030)
    • 9.3.2 Brazil Isocitrate Dehydrogenase Inhibitors Market Size and Forecast (2019-2030)
    • 9.3.3 Argentina Isocitrate Dehydrogenase Inhibitors Market Size and Forecast (2019-2030)

10 Middle East & Africa

  • 10.1 Middle East & Africa Isocitrate Dehydrogenase Inhibitors Consumption Value by Type (2019-2030)
  • 10.2 Middle East & Africa Isocitrate Dehydrogenase Inhibitors Consumption Value by Application (2019-2030)
  • 10.3 Middle East & Africa Isocitrate Dehydrogenase Inhibitors Market Size by Country
    • 10.3.1 Middle East & Africa Isocitrate Dehydrogenase Inhibitors Consumption Value by Country (2019-2030)
    • 10.3.2 Turkey Isocitrate Dehydrogenase Inhibitors Market Size and Forecast (2019-2030)
    • 10.3.3 Saudi Arabia Isocitrate Dehydrogenase Inhibitors Market Size and Forecast (2019-2030)
    • 10.3.4 UAE Isocitrate Dehydrogenase Inhibitors Market Size and Forecast (2019-2030)

11 Market Dynamics

  • 11.1 Isocitrate Dehydrogenase Inhibitors Market Drivers
  • 11.2 Isocitrate Dehydrogenase Inhibitors Market Restraints
  • 11.3 Isocitrate Dehydrogenase Inhibitors Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Isocitrate Dehydrogenase Inhibitors Industry Chain
  • 12.2 Isocitrate Dehydrogenase Inhibitors Upstream Analysis
  • 12.3 Isocitrate Dehydrogenase Inhibitors Midstream Analysis
  • 12.4 Isocitrate Dehydrogenase Inhibitors Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Isocitrate Dehydrogenase Inhibitors . Industry analysis & Market Report on Isocitrate Dehydrogenase Inhibitors is a syndicated market report, published as Global Isocitrate Dehydrogenase Inhibitors Market 2024 by Company, Regions, Type and Application, Forecast to 2030. It is complete Research Study and Industry Analysis of Isocitrate Dehydrogenase Inhibitors market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,690.04
    		4,035.06
    		5,380.08
    		3,239.88
    		4,859.82
    		6,479.76
    		531,361.20
    		797,041.80
    		1,062,722.40
    		293,712.00
    		440,568.00
    		587,424.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo